Augmented mast cell infiltration and microvessel density in prostate cancer

Wspolczesna Onkologia

Volumn 17, Issue 4, 2013, Pages 378-382

  Stawerski, Paweł ^a   Wagrowska Danilewicz, Małgorzata ^a   Stasikowska Kanicka, Olga ^a   Tuka, Elzbieta ^b   Danilewicz, Marian ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Pathology   (Poland)

Author keywords

Mast cells; Microvessel density; Prostate cancer

Indexed keywords

CD34 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TRYPTASE;

ARTICLE; CAPILLARY DENSITY; CELL FUNCTION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MALE; MAST CELL; NEEDLE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 84885992777     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.37220     Document Type: Article

References (28)

1. Schröder FH. Screening for prostate cancer. Urol Clin North Am 2003; 30: 239-51. (Pubitemid 36520598)
2. Dobruch J, Borówka A, Antoniewicz A, Chlosta P. Epidemiologia raka gruczolu krokowego: zmiany obserwowane wPolsce wlatach 1991- 2000. Urol Pol 2005; 58: 1.
3. Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010; 177: 1031-41.
4. Nassif AE, Tâmbara Filho R. Immunohistochemistry expression of tumour markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Rev Col Bras Cir 2010; 37: 338-44.
5. Nonomura N, Takayama H, Nishimura K, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007; 97: 952-6. (Pubitemid 47519307)
6. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Micro - vessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-7. (Pubitemid 34777895)
7. Dyduch G, Kaczmarczyk K, Okoń K. Mast cells and cancer: enemies or allies? Pol J Pathol 2012; 63: 1-7.
8. Yang J, Wu HF, Qian LX, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumour progression. Asian J Androl 2006; 8: 169-75. (Pubitemid 43349187)
9. de la Taille A, Katz AE, Bagiella E, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 2000; 113: 555-62. (Pubitemid 30217365)
10. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-700.
11. Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 2004; 18: 155-60. (Pubitemid 38488998)
12. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-2012. (Pubitemid 47354167)
13. Cébe Suarez S, Pieren M, Cariolato, L et al. AVEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006; 63: 2067-77. (Pubitemid 44359746)
14. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267-85.
15. Lafleur MA, Handsley MM, Edwards DR.Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 2003; 22: 1-39.
16. Abdou AG, Aiad H, Asaad N, Abd El-Wahed M, Serag El-Dien M. Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma. J Egypt Natl Canc Inst 2006; 18: 311-22.
17. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 2009; 24: 1265-75.
18. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z. Association of mast cells with microvessel density in renal cell carcinomas. Eur Urol 2006; 50: 530-4. (Pubitemid 44189044)
19. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000; 88: 2686-92. (Pubitemid 30417928)
20. Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 antigen). Prostate Cancer Prostatic Dis 1997; 1: 32-8. (Pubitemid 127537062)
21. Ahmadi SA, Moinfar M, Gohari Moghaddam K, Bahadori M. Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med 2010; 13: 498-503.
22. Mohseni MG, Mohammadi A, Heshmat AS, Kosari F, Meysamie AP. The lack of correlation between mast cells and microvessel density with pathologic feature of renal cell carcinoma. Int Urol Nephrol 2010; 42: 109-12.
23. da Motta VP, Malafaia O, Ribas-Filho JM, Czeczko NG, Ribas CA, Cuenca RM. CASPASE-3 and CD-34 expression in prostate adenocarcinoma. Rev Col Bras Cir 2009; 36: 223-9.
24. Aydin O, Dusmez D, Cinel L, Doruk E, Kanik A. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 2002; 198: 267-71. (Pubitemid 34495573)
25. Fleischmann A, Schlomm T, Köllermann J, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumour characteristics and good prognosis. Prostate 2009; 69: 976-81.
26. Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 2012; 72: 831-5.
27. Dyduch G, Okoń K, Pescarini E. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study. Pol J Pathol 2011; 62: 139-44.
28. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111: 486-94.